InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,185.35
(
-0.05%
)
US TECH 100
17,574.40
(
-0.22%
)
Dow Jones
38,919.65
(
0.09%
)
Brent Oil
82.57
(
-0.36%
)
Bitcoin
62,488.93
(
0.25%
)
Post# of 30990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

NukeJohn

Send PM Follow Ignore
Followers 81
Posts 1964
Boards Moderated 0
Alias Born 11/12/2003

NukeJohn

Re: jay10 post# 20543

Tuesday, 09/02/2014 4:29:48 PM

Tuesday, September 02, 2014 4:29:48 PM

Post# of 30990
Nice Find...Read the bottom of page 9

Here is the link....

http://omicsgroup.org/journals/anatabine-attenuates-tau-phosphorylation-and-oligomerization-in-ps-tau-transgenic-mice-2168-975X.1000126.pdf

here is an excerpt worth noting...

It is therefore anticipated that anatabine has the potential to mitigate the three main pathologies associated with AD: tau hyperphosphorylation, Aß accumulation and neuroinflammation.

What would big pharma be willing to pay for something that could really benefit AD patients?

JMHO,

NJ
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up